3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
36
Colonic Neoplasms
10
Rectal Neoplasms
8
Neoplasm Metastasis
8
Neoplasms
5
Pancreatic Neoplasms
2
Carcinoma, Neuroendocrine
2
Adenocarcinoma
2
Stomach Neoplasms
1
Ras-mutated Metastatic Colorectal Cancer
1
Pancreatic Adenocarcinoma Metastatic
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Metastatic Colorectal Adenocarcinoma
1
Liver Metastasis Colon Cancer
1
Gastrointestinal Neoplasms
1
Exanthema
1
Carcinoma, Basal Cell
1
Carcinoma
1
CRC
1
Advanced Cancer
1
Interventions
spartalizumab
1
sapropterin
1
penpulimab
1
niraparib
1
anlotinib
1
Taxes
1
Ipilimumab
1
IFL protocol
1
Gemcitabine
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pancreatic Adenocarcinoma Metastatic
×
IFL protocol
×
Clear all
NCT06747845
2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
68 enrolled